Simponi Aria® (golimumab) – New indication, expanded indication
September 30, 2020 - Janssen announced the FDA approval of Simponi Aria (golimumab), for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
Download PDF
